Literature DB >> 15615650

Tau alteration and neuronal degeneration in tauopathies: mechanisms and models.

Roland Brandt1, Monika Hundelt, Neelam Shahani.   

Abstract

Tau becomes characteristically altered both functionally and structurally in several neurodegenerative diseases now collectively called tauopathies. Although increasing evidence supports that alterations of tau may directly cause neuronal degeneration and cell death, the mechanisms, which render tau to become a toxic agent are still unclear. In addition, it is obscure, whether neurodegeneration in tauopathies occurs via a common mechanism or specific differences exist. The aim of this review is to provide an overview about the different experimental models that currently exist, how they are used to determine the role of tau during degeneration and what has been learnt from them concerning the mechanistic role of tau in the disease process. The review begins with a discussion about similarities and differences in tau alteration in paradigmatic tauopathies such as frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) and Alzheimer's disease (AD). The second part concentrates on major experimental models that have been used to address the mechanistic role of tau during degeneration. This will include a discussion of cell-free assays, culture models using cell lines or dissociated neurons, and animal models. How these models aid to understand (i) alterations in the function of tau as a microtubule-associated protein (MAP), (ii) direct cytotoxicity of altered tau protein, and (iii) the potential role of tau aggregation in neurodegenerative processes will be the central theme of this part. The review ends with concluding remarks about a general mechanistic model of the role of tau alteration and neuronal degeneration in tauopathies and future perspectives.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15615650     DOI: 10.1016/j.bbadis.2004.06.018

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  73 in total

1.  Strategies for diminishing katanin-based loss of microtubules in tauopathic neurodegenerative diseases.

Authors:  Haruka Sudo; Peter W Baas
Journal:  Hum Mol Genet       Date:  2010-11-30       Impact factor: 6.150

2.  Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration.

Authors:  Brian R Hoover; Miranda N Reed; Jianjun Su; Rachel D Penrod; Linda A Kotilinek; Marianne K Grant; Rose Pitstick; George A Carlson; Lorene M Lanier; Li-Lian Yuan; Karen H Ashe; Dezhi Liao
Journal:  Neuron       Date:  2010-12-22       Impact factor: 17.173

3.  Monte carlo simulations of tau proteins: effect of phosphorylation.

Authors:  Y S Jho; E B Zhulina; M W Kim; P A Pincus
Journal:  Biophys J       Date:  2010-10-20       Impact factor: 4.033

4.  The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis.

Authors:  H Bartosik-Psujek; Z Stelmasiak
Journal:  J Neural Transm (Vienna)       Date:  2005-07-06       Impact factor: 3.575

5.  SR protein 9G8 modulates splicing of tau exon 10 via its proximal downstream intron, a clustering region for frontotemporal dementia mutations.

Authors:  Lei Gao; Junning Wang; Yingzi Wang; Athena Andreadis
Journal:  Mol Cell Neurosci       Date:  2006-11-29       Impact factor: 4.314

6.  Can zebrafish be used as animal model to study Alzheimer's disease?

Authors:  Soraya Santana; Eduardo P Rico; Javier S Burgos
Journal:  Am J Neurodegener Dis       Date:  2012-05-15

7.  Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: implication for Alzheimer disease.

Authors:  Zhi Tang; Erika Bereczki; Haiyan Zhang; Shan Wang; Chunxia Li; Xinying Ji; Rui M Branca; Janne Lehtiö; Zhizhong Guan; Peter Filipcik; Shaohua Xu; Bengt Winblad; Jin-Jing Pei
Journal:  J Biol Chem       Date:  2013-04-12       Impact factor: 5.157

Review 8.  Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia.

Authors:  Edward D Huey; Nicole Armstrong; Parastoo Momeni; Jordan Grafman
Journal:  Expert Opin Ther Targets       Date:  2008-11       Impact factor: 6.902

Review 9.  Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease.

Authors:  C-X Gong; K Iqbal
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

Review 10.  Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer's disease.

Authors:  Jangampalli Adi Pradeepkiran; Arubala P Reddy; P Hemachandra Reddy
Journal:  Drug Discov Today       Date:  2018-11-16       Impact factor: 7.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.